The global metabolomics market was valued at USD 3.21 billion in 2025. It is estimated at USD 3.52 billion in 2026 and is projected to reach USD 8.74 billion by 2036, at a CAGR of 9.5% during the forecast period 2026-2036. This report provides a detailed assessment of the market, covering biomarker and drug development demand, population-scale studies, mass spectrometry and NMR technologies, clinical translation and laboratory regulation, pricing, workflow consolidation among instrument makers, the competitive landscape, and future growth opportunities.
The market includes the tools, kits, software, and services that laboratories use to detect and quantify metabolites, the small molecules present in blood, urine, tissue, cells, and microbial and plant samples. Products in scope include LC-MS, GC-MS, CE-MS, mass spectrometry imaging, and NMR systems, targeted kits, standards, reagents, and columns, software for processing, compound identification, and pathway mapping, and contract metabolomics and lipidomics services. Because metabolite levels reflect genes, proteins, diet, gut microbes, medicines, and the environment together, they offer a direct readout of how an organism is functioning. Mass spectrometry and NMR systems used only for non-biological work such as petrochemical and materials analysis, routine clinical chemistry analyzers, and proteomics and genomics products are excluded.
According to Nightingale Health, it completed in November 2025 the release of NMR metabolic profiles covering every one of the 500,000 UK Biobank participants, creating one of the biggest metabolic datasets tied to genetic and health records. Clinical use is also widening: according to Nightingale Health, more than 200,000 people in Finland have received its blood analysis results through occupational health checks with Terveystalo, and in February 2026 the New York State Department of Health granted the company a clinical laboratory permit. Metabolon reports more than 15,000 completed projects and more than 4,000 supported publications over 25 years.
High-resolution mass spectrometers and high-field NMR systems require large capital outlays plus ongoing service, consumable, and facility costs, which limits adoption in smaller academic and clinical laboratories and in emerging economies; tighter research and pharmaceutical budgets can also delay purchases. Workflows need skilled staff for sample preparation, chromatography, instrument operation, data processing, and interpretation, and the shortage of such staff slows large studies and raises the risk of variable results. The chemical diversity of metabolites means no single platform covers the whole metabolome, many signals in untargeted studies cannot be matched to known compounds, and the lack of common methods, reference materials, and reporting formats makes results hard to compare.
Clinical translation into preventive health, risk assessment, and treatment monitoring is the main opportunity, supported by Waters' February 2026 combination with BD's Biosciences and Diagnostic Solutions businesses, which created an Advanced Diagnostics division for regulated clinical testing workflows, among them multiplex LC-MS testing. Standardized quantitative kits, AI software for metabolite identification, and wider use in nutrition, microbiome research, agriculture, and bio-manufacturing offer further openings. Key trends include ion mobility combined with high-resolution mass spectrometry for isomer separation, instrument makers building full workflows of kits, software, and services, and research built on very large metabolic datasets.
By offering, the metabolomics market is segmented into instruments, consumables & kits, software & bioinformatics, and services. In 2026, instruments are expected to hold the largest share, reflecting the high unit value of mass spectrometry and NMR systems, the regular release of new high-resolution platforms such as those shown at ASMS 2026, and steady replacement and upgrade cycles in research, pharmaceutical, and clinical laboratories; within instruments, mass spectrometry systems, led by LC-MS, hold the largest share. Software & bioinformatics is set to record the highest CAGR, as datasets grow larger and more complex, better metabolite identification is needed, and AI analytics and multiomics integration are spreading. Consumables & kits are expected to grow strongly on recurring reagent and column use and wider adoption of standardized kits, while services gain as sponsors outsource large studies.
By approach, the metabolomics market is segmented into untargeted metabolomics and targeted metabolomics. Untargeted metabolomics is expected to account for the larger share in 2026, since discovery research relies on it to capture as many metabolites as possible, uncover new biomarkers and pathways, and generate hypotheses for later validation. Targeted metabolomics is set to grow at the higher CAGR, driven by the need for accurate quantification in large cohorts and clinical studies, the availability of standardized kits that cover more than 1,000 metabolites, and the move of metabolite panels into clinical and preventive testing.
By application, the metabolomics market is segmented into biomarker discovery, drug discovery & development, clinical diagnostics & precision medicine, toxicology & environmental testing, nutrition & food testing, agriculture & plant research, and other applications. Biomarker discovery is expected to hold the largest share in 2026, as academic and pharmaceutical groups use metabolomics widely to find markers of disease, drug response, and toxicity across many disease areas. Clinical diagnostics & precision medicine is set to grow at the highest CAGR, supported by the use of metabolic testing in preventive health checks, Nightingale Health's New York State laboratory permit, and the expansion of LC-MS diagnostic workflows.
By indication, the metabolomics market is segmented into oncology, cardiovascular & metabolic disorders, neurological disorders, inborn errors of metabolism, and other indications. Oncology is expected to account for the largest share in 2026, given the central role of altered metabolism in tumor growth, the heavy use of metabolomics in cancer research, and its role in oncology drug development. Cardiovascular & metabolic disorders are set to record the highest CAGR, as large population studies and preventive programs use metabolic profiles to predict disease risk, and new tools such as Nightingale Health's Lp(a) risk detection test target cardiovascular screening. Inborn errors of metabolism remain an established clinical use, with tandem mass spectrometry routinely used in newborn screening.
By end user, the metabolomics market is segmented into academic & research institutes, pharmaceutical & biotechnology companies, contract research organizations & service providers, hospitals & diagnostic laboratories, and food, nutrition & agriculture companies. Academic & research institutes are expected to hold the largest share in 2026, since universities, institutes, and core facilities own much of the installed instrument base and run a large share of studies. Hospitals & diagnostic laboratories are set to grow at the highest CAGR, driven by clinical translation, wider mass spectrometry-based testing, and the use of metabolic panels in preventive care.
North America is expected to lead the global metabolomics market in 2026, owing to strong research funding, many academic institutions and core facilities, a large pharmaceutical and biotechnology base, and the presence of Agilent Technologies, Thermo Fisher Scientific, Bruker, Waters, and Metabolon. The U.S. is also a major market for clinical mass spectrometry, including newborn screening, and Nightingale Health's New York State permit shows growing interest in metabolic testing in U.S. healthcare. Europe holds a significant share, with the U.K. important through UK Biobank, Germany as a base for Bruker, Austria as home to biocrates, and Finland as an early adopter of clinical metabolic testing, while cohorts in Italy (Moli-sani) and Denmark (Aalborg University) add research demand.
Asia-Pacific is projected to grow at the highest CAGR during the forecast period, driven by rising research spending, large population health programs, and expanding pharmaceutical industries. In Singapore, Thermo Fisher Scientific is working with Precision Health Research, Singapore, on the PRECISE-SG100K study, while Japan hosts Shimadzu, JEOL, and Human Metabolome Technologies. China is expected to hold the largest share in the region, supported by heavy research investment and a fast-growing life science sector, and South Korea, India, and Australia are expected to grow strongly. Latin America and the Middle East & Africa hold smaller shares, with food and agricultural research in Brazil and Mexico and national precision medicine efforts in the Gulf, notably Saudi Arabia, the UAE, and Qatar, supporting demand.
Large analytical instrument makers hold a significant part of the metabolomics market, with Thermo Fisher Scientific, Agilent Technologies, Waters, Bruker, SCIEX, and Shimadzu leading in instruments and Bruker and JEOL supplying NMR systems, alongside kit and software specialists and contract service providers. Vendors compete on instrument performance, complete workflows, standardized kits, AI software, and service capacity. Leading players are moving from hardware into full workflows through acquisitions and partnerships, including Bruker's purchase of biocrates in June 2025 after earlier deals for PreOmics and Biognosys, Waters' combination with BD's biosciences and diagnostics businesses, and Thermo Fisher Scientific's PRECISE-SG100K collaboration.
Key companies profiled in the report include Thermo Fisher Scientific Inc. (U.S.), Agilent Technologies, Inc. (U.S.), Waters Corporation (U.S.), Bruker Corporation (U.S.), Danaher Corporation (SCIEX) (U.S.), Shimadzu Corporation (Japan), JEOL Ltd. (Japan), LECO Corporation (U.S.), Metabolon, Inc. (U.S.), Nightingale Health Plc (Finland), and Human Metabolome Technologies, Inc. (Japan).
The market includes the tools, kits, software, and services that laboratories use to detect and quantify metabolites, the small molecules present in blood, urine, tissue, cells, and microbial and plant samples. Products in scope include LC-MS, GC-MS, CE-MS, mass spectrometry imaging, and NMR systems, targeted kits, standards, reagents, and columns, software for processing, compound identification, and pathway mapping, and contract metabolomics and lipidomics services. Because metabolite levels reflect genes, proteins, diet, gut microbes, medicines, and the environment together, they offer a direct readout of how an organism is functioning. Mass spectrometry and NMR systems used only for non-biological work such as petrochemical and materials analysis, routine clinical chemistry analyzers, and proteomics and genomics products are excluded.
According to Nightingale Health, it completed in November 2025 the release of NMR metabolic profiles covering every one of the 500,000 UK Biobank participants, creating one of the biggest metabolic datasets tied to genetic and health records. Clinical use is also widening: according to Nightingale Health, more than 200,000 people in Finland have received its blood analysis results through occupational health checks with Terveystalo, and in February 2026 the New York State Department of Health granted the company a clinical laboratory permit. Metabolon reports more than 15,000 completed projects and more than 4,000 supported publications over 25 years.
Market Dynamics
Biomarker discovery and drug development are the leading drivers of the metabolomics market, because metabolite profiles directly reflect disease activity, drug response, and toxicity, and drug developers use them to find targets, study mechanism of action, track pharmacodynamic effects, check safety, and stratify trial patients. Population cohorts that link metabolic, genetic, and health record data are a second driver, as they need very large sample volumes analyzed to consistent quality. New instruments add further demand: at the June 2026 ASMS conference, Thermo Fisher Scientific, Waters, Bruker, and Shimadzu introduced new high-resolution, ion mobility, or triple quadrupole systems and SCIEX expanded its ZenoTOF 8600 platform, offering higher sensitivity, faster scanning, and better isomer separation. Growing use of multiomics, which combines metabolite data with genomic and protein data, is also pulling metabolomics into wider life science research.High-resolution mass spectrometers and high-field NMR systems require large capital outlays plus ongoing service, consumable, and facility costs, which limits adoption in smaller academic and clinical laboratories and in emerging economies; tighter research and pharmaceutical budgets can also delay purchases. Workflows need skilled staff for sample preparation, chromatography, instrument operation, data processing, and interpretation, and the shortage of such staff slows large studies and raises the risk of variable results. The chemical diversity of metabolites means no single platform covers the whole metabolome, many signals in untargeted studies cannot be matched to known compounds, and the lack of common methods, reference materials, and reporting formats makes results hard to compare.
Clinical translation into preventive health, risk assessment, and treatment monitoring is the main opportunity, supported by Waters' February 2026 combination with BD's Biosciences and Diagnostic Solutions businesses, which created an Advanced Diagnostics division for regulated clinical testing workflows, among them multiplex LC-MS testing. Standardized quantitative kits, AI software for metabolite identification, and wider use in nutrition, microbiome research, agriculture, and bio-manufacturing offer further openings. Key trends include ion mobility combined with high-resolution mass spectrometry for isomer separation, instrument makers building full workflows of kits, software, and services, and research built on very large metabolic datasets.
Segment Analysis
The report analyzes the market by offering, approach, application, indication, end user, and geography, helping stakeholders identify the most attractive areas for product development, partnering, and investment.By offering, the metabolomics market is segmented into instruments, consumables & kits, software & bioinformatics, and services. In 2026, instruments are expected to hold the largest share, reflecting the high unit value of mass spectrometry and NMR systems, the regular release of new high-resolution platforms such as those shown at ASMS 2026, and steady replacement and upgrade cycles in research, pharmaceutical, and clinical laboratories; within instruments, mass spectrometry systems, led by LC-MS, hold the largest share. Software & bioinformatics is set to record the highest CAGR, as datasets grow larger and more complex, better metabolite identification is needed, and AI analytics and multiomics integration are spreading. Consumables & kits are expected to grow strongly on recurring reagent and column use and wider adoption of standardized kits, while services gain as sponsors outsource large studies.
By approach, the metabolomics market is segmented into untargeted metabolomics and targeted metabolomics. Untargeted metabolomics is expected to account for the larger share in 2026, since discovery research relies on it to capture as many metabolites as possible, uncover new biomarkers and pathways, and generate hypotheses for later validation. Targeted metabolomics is set to grow at the higher CAGR, driven by the need for accurate quantification in large cohorts and clinical studies, the availability of standardized kits that cover more than 1,000 metabolites, and the move of metabolite panels into clinical and preventive testing.
By application, the metabolomics market is segmented into biomarker discovery, drug discovery & development, clinical diagnostics & precision medicine, toxicology & environmental testing, nutrition & food testing, agriculture & plant research, and other applications. Biomarker discovery is expected to hold the largest share in 2026, as academic and pharmaceutical groups use metabolomics widely to find markers of disease, drug response, and toxicity across many disease areas. Clinical diagnostics & precision medicine is set to grow at the highest CAGR, supported by the use of metabolic testing in preventive health checks, Nightingale Health's New York State laboratory permit, and the expansion of LC-MS diagnostic workflows.
By indication, the metabolomics market is segmented into oncology, cardiovascular & metabolic disorders, neurological disorders, inborn errors of metabolism, and other indications. Oncology is expected to account for the largest share in 2026, given the central role of altered metabolism in tumor growth, the heavy use of metabolomics in cancer research, and its role in oncology drug development. Cardiovascular & metabolic disorders are set to record the highest CAGR, as large population studies and preventive programs use metabolic profiles to predict disease risk, and new tools such as Nightingale Health's Lp(a) risk detection test target cardiovascular screening. Inborn errors of metabolism remain an established clinical use, with tandem mass spectrometry routinely used in newborn screening.
By end user, the metabolomics market is segmented into academic & research institutes, pharmaceutical & biotechnology companies, contract research organizations & service providers, hospitals & diagnostic laboratories, and food, nutrition & agriculture companies. Academic & research institutes are expected to hold the largest share in 2026, since universities, institutes, and core facilities own much of the installed instrument base and run a large share of studies. Hospitals & diagnostic laboratories are set to grow at the highest CAGR, driven by clinical translation, wider mass spectrometry-based testing, and the use of metabolic panels in preventive care.
Regional Analysis
The report covers North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa, spanning 22 countries and four rest-of-region groups. The regional analysis of the metabolomics market considers research funding, population cohort programs, pharmaceutical activity, clinical laboratory adoption, and the presence of instrument makers and service providers.North America is expected to lead the global metabolomics market in 2026, owing to strong research funding, many academic institutions and core facilities, a large pharmaceutical and biotechnology base, and the presence of Agilent Technologies, Thermo Fisher Scientific, Bruker, Waters, and Metabolon. The U.S. is also a major market for clinical mass spectrometry, including newborn screening, and Nightingale Health's New York State permit shows growing interest in metabolic testing in U.S. healthcare. Europe holds a significant share, with the U.K. important through UK Biobank, Germany as a base for Bruker, Austria as home to biocrates, and Finland as an early adopter of clinical metabolic testing, while cohorts in Italy (Moli-sani) and Denmark (Aalborg University) add research demand.
Asia-Pacific is projected to grow at the highest CAGR during the forecast period, driven by rising research spending, large population health programs, and expanding pharmaceutical industries. In Singapore, Thermo Fisher Scientific is working with Precision Health Research, Singapore, on the PRECISE-SG100K study, while Japan hosts Shimadzu, JEOL, and Human Metabolome Technologies. China is expected to hold the largest share in the region, supported by heavy research investment and a fast-growing life science sector, and South Korea, India, and Australia are expected to grow strongly. Latin America and the Middle East & Africa hold smaller shares, with food and agricultural research in Brazil and Mexico and national precision medicine efforts in the Gulf, notably Saudi Arabia, the UAE, and Qatar, supporting demand.
Competitive Landscape
The report provides a detailed review of the competitive landscape, covering key growth strategies, competitive benchmarking, the competitive dashboard with market leaders, market differentiators, vanguards, and emerging players, and market share/rank analysis by key player for 2025. Company profiles include business overviews, financial performance, product portfolios, strategic developments, and SWOT analyses.Large analytical instrument makers hold a significant part of the metabolomics market, with Thermo Fisher Scientific, Agilent Technologies, Waters, Bruker, SCIEX, and Shimadzu leading in instruments and Bruker and JEOL supplying NMR systems, alongside kit and software specialists and contract service providers. Vendors compete on instrument performance, complete workflows, standardized kits, AI software, and service capacity. Leading players are moving from hardware into full workflows through acquisitions and partnerships, including Bruker's purchase of biocrates in June 2025 after earlier deals for PreOmics and Biognosys, Waters' combination with BD's biosciences and diagnostics businesses, and Thermo Fisher Scientific's PRECISE-SG100K collaboration.
Key companies profiled in the report include Thermo Fisher Scientific Inc. (U.S.), Agilent Technologies, Inc. (U.S.), Waters Corporation (U.S.), Bruker Corporation (U.S.), Danaher Corporation (SCIEX) (U.S.), Shimadzu Corporation (Japan), JEOL Ltd. (Japan), LECO Corporation (U.S.), Metabolon, Inc. (U.S.), Nightingale Health Plc (Finland), and Human Metabolome Technologies, Inc. (Japan).
How This Report Helps
- Provides reliable market size estimates and long-term forecasts for the global metabolomics market.
- Explains how biomarker discovery, drug development, population cohorts, and multiomics research are shaping demand.
- Assesses the impact of instrument costs, skills shortages, metabolite identification limits, and the lack of standardization.
- Identifies high-growth opportunities across offering, approach, application, indication, end user, and region.
- Tracks new high-resolution and ion mobility platforms, standardized kits, AI software, and clinical metabolic testing.
- Benchmarks leading companies by instrument portfolio, workflow coverage, kits, software, services, and acquisitions.
- Supports product planning, partnering, acquisition screening, service expansion, and market entry decisions for instrument makers, kit and software providers, service companies, and investors.
Key Questions Answered
- How big is the global metabolomics market today, and how will it grow through 2036?
- What are the main drivers, restraints, opportunities, challenges, and trends shaping the market?
- How are population-scale programs such as UK Biobank and PRECISE-SG100K changing demand for metabolomics?
- Which offering, approach, application, indication, and end-user segments will grow the fastest?
- How quickly will targeted assays and standardized kits be adopted in large studies and clinical research?
- How is metabolomics moving into clinical diagnostics and preventive healthcare?
- Which regions and countries offer the most attractive business opportunities?
- Who are the leading companies, and how are acquisitions and new platforms changing the competitive landscape?
Table of Contents
1. Introduction
2. Research Methodology
4. Market Overview
5. Metabolomics Market, by Offering
6. Metabolomics Market, by Approach
7. Metabolomics Market, by Application
8. Metabolomics Market, by Indication
9. Metabolomics Market, by End User
10. Metabolomics Market, by Geography
11. Competitive Landscape
12. Company Profiles
13. Appendix
LIST OF TABLES
LIST OF FIGURES
Companies Mentioned
- Thermo Fisher Scientific Inc.
- Agilent Technologies, Inc.
- Waters Corporation
- Bruker Corporation
- Danaher Corporation
- Shimadzu Corporation
- JEOL Ltd.
- LECO Corporation
- Metabolon, Inc.
- Nightingale Health Plc
- Human Metabolome Technologies, Inc.
